4.6 Article

Prevalence of atheromatous and non-atheromatous cardiovascular disease by age in chronic kidney disease

Journal

NEPHROLOGY DIALYSIS TRANSPLANTATION
Volume 35, Issue 5, Pages 827-836

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfy277

Keywords

cardiovascular disease; chronic kidney disease; elderly; epidemiology; risk factors

Funding

  1. Agence Nationale de la Recherche through the 2010 Cohortes-Investissements d'Avenir program
  2. national Programme Hospitalier de Recherche Clinique
  3. Amgen
  4. Baxter
  5. Fresenius Medical Care
  6. GlaxoSmithKline (GSK)
  7. Merck Sharp & Dohme-Chibret (MSD France)
  8. Lilly France
  9. Otsuka Pharmaceutical
  10. Sanofi-Genzyme

Ask authors/readers for more resources

Background. Although chronic kidney disease (CKD) and age are major risk factors for cardiovascular disease (CVD), little is known about the relative proportions of atheromatous and non-atheromatous CVD by age in CKD patients. Methods. We used baseline data from the French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort of 3033 patients (65% men) with CKD Stages 3-4 to study crude and adjusted associations between age, the estimated glomerular filtration rate (eGFR), atheromatous CVD (coronary artery disease, peripheral artery disease and stroke) and non-atheromatous CVD (heart failure, cardiac arrhythmia and valvular heart disease). Results. Mean age was 66.8 and mean Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR was 32.9 mL/min/1.73 m(2). In the <65, (65-74), (75-84) and >= 85 year age groups, the prevalence was, respectively, 18.7, 35.5, 42.9 and 37.8% for atheromatous CVD, and 14.9, 28.4, 38.1 and 56.4% for non-atheromatous CVD. After adjusting for albuminuria, sex and CVD risk factors, the odds ratio (OR) [95% confidence interval (CI)] for (65-74), (75-84) and >= 85 age groups (compared with the <65 group) was, respectively, 1.99 (1.61-2.46), 2.89 (2.30-3.62), 2.72 (1.77-4.18) for atheromatous CVD and 2.07 (1.66-2.58), 3.15 (2.50-3.97), 7.04 (4.67-10.61) for nonatheromatous CVD. Compared with patients with an eGFR >30 mL/min/1.73 m(2), those with an eGFR <30 mL/min/1.73 m(2) had a higher OR for atheromatous CVD [1.21 (1.01-1.44)] and non-atheromatous CVD [1.16 (0.97-1.38)]. Conclusions. In this large cohort of CKD patients, both atheromatous and non-atheromatous CVD were highly prevalent and more frequent in older patients. In a given age group, the prevalence of atheromatous and non-atheromatous CVD was similar (except for a greater prevalence of non-atheromatous CVD after 85).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available